Details for New Drug Application (NDA): 020841
✉ Email this page to a colleague
The generic ingredient in LOTEMAX is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for 020841
Tradename: | LOTEMAX |
Applicant: | Pharmos |
Ingredient: | loteprednol etabonate |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020841
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.5% | ||||
Approval Date: | Mar 9, 1998 | TE: | RLD: | No |
Expired US Patents for NDA 020841
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription